阅读说明：本技术 羽扇豆醇在制备预防或治疗肝损伤药物中的应用 (Application of lupeol in preparation of medicine for preventing or treating liver injury ) 是由 吕志平 黄莎 曾婷 莫婵 周楚莹 赖瑜琪 于 2019-09-03 设计创作，主要内容包括：本发明公开了羽扇豆醇在制备预防或治疗肝损伤药物中的应用,本发明表明,在LPS诱导的斑马鱼肝损伤模型中,羽扇豆醇能增加LPS导致的斑马鱼肝脏面积,H&E染色显示羽扇豆醇能减轻肝细胞变性,肿大；TUNEL染色显示羽扇豆醇能减轻肝细胞凋亡；LPS刺激RAW264.5体外细胞模型中,羽扇豆醇显示抗炎活性,具有减轻INOS水平,降低TNF-α水平；因此羽扇豆醇恢复了LPS引起的肝损伤。(The invention discloses an application of lupeol in preparing a medicine for preventing or treating liver injury, and the application shows that in a zebra fish liver injury model induced by LPS, lupeol can increase the liver area of zebra fish caused by LPS, and H & E staining shows that the lupeol can relieve liver cell degeneration and swelling; TUNEL staining showed lupeol to reduce hepatocyte apoptosis; in an LPS stimulated RAW264.5 in vitro cell model, lupeol shows anti-inflammatory activity, has functions of reducing INOS level and reducing TNF-alpha level; thus lupeol restored LPS-induced liver damage.)

1. Application of lupeol in preparing medicine for preventing or treating liver injury is provided.

2. The use of claim 1, wherein: the liver injury is liver injury caused by lipopolysaccharide.

3. The use of claim 1, wherein: the medicine consists of active ingredient lupeol and pharmaceutic adjuvant.

4. The use of claim 1, wherein: the dosage form of the medicine is oral dosage form or injection dosage form.

5. Use of lupeol in the manufacture of a medicament for reducing the level of INOS expression and the level of TNF-a expression in macrophages.

Technical Field

The invention belongs to the field of medicines, and relates to application of lupeol in preparation of a medicine for preventing or treating liver injury.

Background

Acute Liver Injury (ALI) threatens human health. Infiltration of mononuclear phagocytes into the liver is associated with the severity of liver injury during which resident macrophages, known as Kupffer Cells (KCs), participate in the initial stress response and are widely recognized as one of the major cell types responsible for ALI, releasing various metabolites that cause cell damage, including superoxide radicals, nitric oxide, eicosanoids, proteases, and pro-inflammatory cytokines, among others. Lipopolysaccharide (LPS) can cause KCs to significantly secrete pro-inflammatory mediators and ultimately endotoxin-induced liver damage.

Lupeol (Lupeol) belongs to the pentacyclic terpene type triterpenes, which are present in edible vegetables, fruits and many plants. Molecular formula C₃₀H₅₀O, molecular weight 426.72, structural formula as follows:

many studies have shown that lupeol has many beneficial pharmacological activities, including antioxidant, anti-inflammatory, antihyperglycemic, antilipemic and anti-cancer effects. From various animal models targeting diseases, these reports indicate that lupeol has antidiabetic, antiasthmatic, antiarthritic, cardioprotective, hepatoprotective, nephroprotective, neuroprotective and anticancer effects in various routes of administration such as topical, oral, subcutaneous, intraperitoneal.

Disclosure of Invention

The invention aims to provide application of lupeol in preparation of a medicine for preventing or treating liver injury.

The purpose of the invention is realized as follows: application of lupeol in preparing medicine for preventing or treating liver injury is provided.

The liver injury is liver injury caused by lipopolysaccharide.

The medicine consists of active ingredient lupeol and pharmaceutic adjuvant.

The dosage form of the medicine is oral dosage form or injection dosage form.

Use of lupeol in the manufacture of a medicament for reducing the level of INOS expression and the level of TNF-a expression in macrophages.

The invention shows that in a zebra fish liver injury model induced by LPS, lupeol can increase the liver area of zebra fish caused by LPS, and H & E staining shows that lupeol can relieve hepatocyte degeneration and enlargement; TUNEL staining showed lupeol to reduce hepatocyte apoptosis; in an in vitro cell model of RAW264.5 stimulated by LPS, lupeol shows anti-inflammatory activity, has functions of reducing INOS level and reducing TNF-alpha level, so that lupeol recovers liver injury caused by LPS and can be used as a medicine for treating liver injury.

Drawings

FIG. 1 shows the liver morphology of the zebrafish embryo Control group (Control), Model group (Model) and administration group of example 1.

FIG. 2 shows the results of H & E pathological staining of the zebra fish embryo of example 1 in the Control group (Control), Model group (Model), DMSO group, and administration group.

FIG. 3 shows the TUNEL staining results of the zebrafish embryo Control (Control), Model (Model) and administration groups of example 1.

FIGS. 4 and 5 are graphs showing the effect of lupeol from example 1 on INOS expression in RAW264.7 cells.

FIG. 6 is the effect of lupeol from example 1 on ITNF- α expression in RAW264.7 cells.

Detailed Description

The invention relates to an application of lupeol in preparing a medicine for preventing or treating liver injury. Preferably, the liver damage is liver damage caused by LPS. The medicine consists of active ingredient lupeol and pharmaceutic adjuvant. The medicament can be prepared into oral dosage forms or injection dosage forms. Preferably, lupeol is used in the manufacture of a medicament for reducing the level of INOS expression and TNF-a expression in macrophages.

The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto.